RCS - Hutchmed China Ltd - HUTCHMED Included in FTSE Russell Indexes

HUTCHMED (China)Announcement

20/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST0762Wa&default-theme=true

RNS Number : 0762W  Hutchmed (China) Limited  20 December 2021

Press Release

 

HUTCHMED Included in FTSE Russell Indexes

 

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, December 20, 2021:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE
Russell in the FTSE Global Equity Index Series ("GEIS") in its quarterly
review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total
Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on
Monday, December 20, 2021.

 

FTSE Russell is a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset classes in
more than 70 countries, covering 98% of the investable market globally. The
FTSE GEIS provides a robust global equity index framework and includes over
16,000 large, mid, small and micro-cap securities across 49 developed and
emerging markets globally, with a wide range of modular indexes available to
target specific markets and market segments.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
develop-ment and commercial-ization of targeted therapies and immuno-therapies
for the treatment of cancer and immuno-logical diseases. It has more than
4,500 personnel across all its companies, at the center of which is a team of
over 1,400 in oncology/immunology. Since inception it has advanced 11 cancer
drug candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch-med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including its inclusion in FTSE Russell
Indexes. Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions regarding
HUTCHMED's financial condition and results of operations, general economic,
regulatory and political conditions and the impact of COVID-19 on any of the
foregoing. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the U.S. Securities and Exchange Commission, on AIM and with The
Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

Solebury Trout
bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

FTI Consulting
HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

Brunswick

                                    HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEADAXFEAFFFA